Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma

Makoto Nakano, Chiharu Sogawa, Norio Sogawa, Katsuaki Mishima, Eiki Yamachika, Nobuyoshi Mizukawa, Joji Fukunaga, Tomoaki Kawamoto, Koichi Sawaki, Toshio Sugahara, Hiroaki Furuta

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Cisplatin (CDDP) is a useful drug for the treatment of malignant solid tumors of the head and neck. Because CDDP includes the heavy metal platinum as a component, it is thought metallothionein (MT) may be involved in CDDP-resistance. However, functional differences between the four MT isoforms (MT-I, II, III and IV) remain unclear. The aim of this study was to investigate the relationship between MT isoform expression and CDDP-resistance. Two human tongue squamous cell carcinoma cell lines not exposed to anticancer chemotherapy were studied. The cell lines were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis before and after CDDP-treatment. Both cell lines expressed MT-I/II and MT-IV isoforms but not the MT-III isoform. Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line. Our results showed that expression of the MT I/II isoform was induced by CDDP treatment, and may play an important role in CDDP-resistance in squamous cell carcinoma of the human tongue.

Original languageEnglish
Pages (from-to)299-303
Number of pages5
JournalAnticancer Research
Volume23
Issue number1 A
Publication statusPublished - Jan 2003

Fingerprint

Metallothionein
Cisplatin
Squamous Cell Carcinoma
Protein Isoforms
Cell Line
Tongue
Therapeutics
Heavy Metals
Platinum
Reverse Transcriptase Polymerase Chain Reaction
Neck
Head

Keywords

  • Cell line
  • Experimental study
  • Human
  • In vitro
  • Metallothionein isoforms
  • Squamous cell carcinoma
  • Tongue

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma. / Nakano, Makoto; Sogawa, Chiharu; Sogawa, Norio; Mishima, Katsuaki; Yamachika, Eiki; Mizukawa, Nobuyoshi; Fukunaga, Joji; Kawamoto, Tomoaki; Sawaki, Koichi; Sugahara, Toshio; Furuta, Hiroaki.

In: Anticancer Research, Vol. 23, No. 1 A, 01.2003, p. 299-303.

Research output: Contribution to journalArticle

Nakano, M, Sogawa, C, Sogawa, N, Mishima, K, Yamachika, E, Mizukawa, N, Fukunaga, J, Kawamoto, T, Sawaki, K, Sugahara, T & Furuta, H 2003, 'Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma', Anticancer Research, vol. 23, no. 1 A, pp. 299-303.
Nakano, Makoto ; Sogawa, Chiharu ; Sogawa, Norio ; Mishima, Katsuaki ; Yamachika, Eiki ; Mizukawa, Nobuyoshi ; Fukunaga, Joji ; Kawamoto, Tomoaki ; Sawaki, Koichi ; Sugahara, Toshio ; Furuta, Hiroaki. / Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma. In: Anticancer Research. 2003 ; Vol. 23, No. 1 A. pp. 299-303.
@article{844dc027e98a4fe9966587d7926ca41c,
title = "Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma",
abstract = "Cisplatin (CDDP) is a useful drug for the treatment of malignant solid tumors of the head and neck. Because CDDP includes the heavy metal platinum as a component, it is thought metallothionein (MT) may be involved in CDDP-resistance. However, functional differences between the four MT isoforms (MT-I, II, III and IV) remain unclear. The aim of this study was to investigate the relationship between MT isoform expression and CDDP-resistance. Two human tongue squamous cell carcinoma cell lines not exposed to anticancer chemotherapy were studied. The cell lines were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis before and after CDDP-treatment. Both cell lines expressed MT-I/II and MT-IV isoforms but not the MT-III isoform. Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line. Our results showed that expression of the MT I/II isoform was induced by CDDP treatment, and may play an important role in CDDP-resistance in squamous cell carcinoma of the human tongue.",
keywords = "Cell line, Experimental study, Human, In vitro, Metallothionein isoforms, Squamous cell carcinoma, Tongue",
author = "Makoto Nakano and Chiharu Sogawa and Norio Sogawa and Katsuaki Mishima and Eiki Yamachika and Nobuyoshi Mizukawa and Joji Fukunaga and Tomoaki Kawamoto and Koichi Sawaki and Toshio Sugahara and Hiroaki Furuta",
year = "2003",
month = "1",
language = "English",
volume = "23",
pages = "299--303",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 A",

}

TY - JOUR

T1 - Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma

AU - Nakano, Makoto

AU - Sogawa, Chiharu

AU - Sogawa, Norio

AU - Mishima, Katsuaki

AU - Yamachika, Eiki

AU - Mizukawa, Nobuyoshi

AU - Fukunaga, Joji

AU - Kawamoto, Tomoaki

AU - Sawaki, Koichi

AU - Sugahara, Toshio

AU - Furuta, Hiroaki

PY - 2003/1

Y1 - 2003/1

N2 - Cisplatin (CDDP) is a useful drug for the treatment of malignant solid tumors of the head and neck. Because CDDP includes the heavy metal platinum as a component, it is thought metallothionein (MT) may be involved in CDDP-resistance. However, functional differences between the four MT isoforms (MT-I, II, III and IV) remain unclear. The aim of this study was to investigate the relationship between MT isoform expression and CDDP-resistance. Two human tongue squamous cell carcinoma cell lines not exposed to anticancer chemotherapy were studied. The cell lines were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis before and after CDDP-treatment. Both cell lines expressed MT-I/II and MT-IV isoforms but not the MT-III isoform. Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line. Our results showed that expression of the MT I/II isoform was induced by CDDP treatment, and may play an important role in CDDP-resistance in squamous cell carcinoma of the human tongue.

AB - Cisplatin (CDDP) is a useful drug for the treatment of malignant solid tumors of the head and neck. Because CDDP includes the heavy metal platinum as a component, it is thought metallothionein (MT) may be involved in CDDP-resistance. However, functional differences between the four MT isoforms (MT-I, II, III and IV) remain unclear. The aim of this study was to investigate the relationship between MT isoform expression and CDDP-resistance. Two human tongue squamous cell carcinoma cell lines not exposed to anticancer chemotherapy were studied. The cell lines were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis before and after CDDP-treatment. Both cell lines expressed MT-I/II and MT-IV isoforms but not the MT-III isoform. Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line. Our results showed that expression of the MT I/II isoform was induced by CDDP treatment, and may play an important role in CDDP-resistance in squamous cell carcinoma of the human tongue.

KW - Cell line

KW - Experimental study

KW - Human

KW - In vitro

KW - Metallothionein isoforms

KW - Squamous cell carcinoma

KW - Tongue

UR - http://www.scopus.com/inward/record.url?scp=0344405741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344405741&partnerID=8YFLogxK

M3 - Article

C2 - 12680227

AN - SCOPUS:0344405741

VL - 23

SP - 299

EP - 303

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -